Enanta Pharmaceuticals
ENTA
133 hedge funds and large institutions have $338M invested in Enanta Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 49 increasing their positions, 33 reducing their positions, and 21 closing their positions.
131% more call options, than puts
Call options by funds: $496K | Put options by funds: $215K
48% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 33
1% more capital inflows, than outflows
Capital inflows: $28.8M | Capital outflows: $28.3M
0.82% more ownership
Funds ownership: 91.43% → 92.26% (+0.82%)
1% more funds holding
Funds holding: 132 → 133 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Spruce Street Capital
New York
|
+$7.28M |
| 2 |
Millennium Management
New York
|
+$2.84M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$2.27M |
| 4 |
Krensavage Asset Management
New York
|
+$1.34M |
| 5 |
Farallon Capital Management
San Francisco,
California
|
+$1.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.92M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$2.35M |
| 3 |
Two Sigma Investments
New York
|
-$2.16M |
| 4 |
Stonepine Capital Management
Bend,
Oregon
|
-$1.58M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.3M |
ENTA Hedge Fund Activity: Q1 2026 in Review
133 of the 8,241 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q1 2026, worth a combined $338M — down 19% from $416M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of ENTA and 19 opened new positions — a net loss of 2 holders — while 33 trimmed existing stakes and 49 added.
The largest buyer was Spruce Street Capital, adding an estimated $7.28M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $6.92M sold.
- 133 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q1 2026, up from 132 in Q4 2025.
- Funds reported $338M of Enanta Pharmaceuticals stock for Q1 2026, down 19% quarter-over-quarter.
- 19 funds opened new Enanta Pharmaceuticals positions in Q1 2026 and 21 closed out, a net change of -2 holders.
- The largest Enanta Pharmaceuticals buyer in Q1 2026 was Spruce Street Capital, an estimated $7.28M added.
- The largest Enanta Pharmaceuticals seller in Q1 2026 was Point72 Asset Management, an estimated $6.92M sold.
Based on aggregated 13F filings for Q1 2026.